PRISM-GENOMICS-Smoking Cessation for Patients With Coronary Artery Disease Undergoing Cardiac Catheterization or Having a Heart Attack at Barnes Hospital in St. Louis Mo

• Status: Active, not recruiting
• Trial end date: 2025-07-21
• Target enrollment: 0
• Participant gender: All

Summary

It has previously been shown that patients with coronary artery disease may have a harder time quitting smoking if they have a specific genetic profile and that these individuals have a better chance at quitting if they receive nicotine replacement therapy. The investigators hypothesize that determining which individuals with coronary artery disease should receive nicotine replacement therapy based on their genotype may improve the number of individuals who are able to quit smoking.This study randomizes treatment to that determined by the patient's genotype compared to standard, non-genotype-guided, treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Adult

• presenting to Barnes hospital cardiac catheterization laboratory with coronary artery disease or admitted to Barnes hospital within 24 hours of a type 1 myocardial infarction (heart attack)

• active smoker at time of presentation to Barnes Hospital

• participating in PRISM-GENOMICS observational study

Exclusion Criteria:

• Unable to provide informed consent

• Unable to answer questions (e.g. intubated)

• Incarcerated

• Complications of myocardial infarction (such as shock, hemodynamic instability, life- threatening infection, etc)

• Women of child-bearing age with positive pregnancy test or who is breast feeding